Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

1.

A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.

Kokabi N, Galt JR, Xing M, Camacho JC, Barron BJ, Schuster DM, Kim HS.

J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007.

PMID:
24461133
[PubMed - in process]
2.

Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.

Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Porée P, Clément B, Raoul JL, Boucher E.

J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235.

PMID:
22302962
[PubMed - indexed for MEDLINE]
Free Article
3.

Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.

Lam MG, Goris ML, Iagaru AH, Mittra ES, Louie JD, Sze DY.

J Nucl Med. 2013 Dec;54(12):2055-61. doi: 10.2967/jnumed.113.123257. Epub 2013 Oct 21.

PMID:
24144563
[PubMed - indexed for MEDLINE]
4.

Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.

Padia SA, Alessio A, Kwan SW, Lewis DH, Vaidya S, Minoshima S.

J Vasc Interv Radiol. 2013 Aug;24(8):1147-53. doi: 10.1016/j.jvir.2013.04.018. Epub 2013 Jun 20.

PMID:
23792126
[PubMed - indexed for MEDLINE]
5.

SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.

Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G.

J Nucl Med. 2009 May;50(5):688-92. doi: 10.2967/jnumed.108.058347. Epub 2009 Apr 16.

PMID:
19372479
[PubMed - indexed for MEDLINE]
Free Article
6.

Outpatient single-session yttrium-90 glass microsphere radioembolization.

Gates VL, Marshall KG, Salzig K, Williams M, Lewandowski RJ, Salem R.

J Vasc Interv Radiol. 2014 Feb;25(2):266-70. doi: 10.1016/j.jvir.2013.11.005. Epub 2013 Dec 12.

PMID:
24332243
[PubMed - in process]
7.

99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.

Wondergem M, Smits ML, Elschot M, de Jong HW, Verkooijen HM, van den Bosch MA, Nijsen JF, Lam MG.

J Nucl Med. 2013 Aug;54(8):1294-301. doi: 10.2967/jnumed.112.117614. Epub 2013 Jun 7.

PMID:
23749996
[PubMed - indexed for MEDLINE]
Free Article
8.

Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization.

Kao YH, Magsombol BM, Toh Y, Tay KH, Chow PKh, Goh AS, Ng DC.

EJNMMI Res. 2014 Jun 29;4:33. doi: 10.1186/s13550-014-0033-7. eCollection 2014.

PMID:
25024931
[PubMed]
Free PMC Article
9.

Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.

Gaba RC, Zivin SP, Dikopf MS, Parvinian A, Casadaban LC, Lu Y, Bui JT.

Radiology. 2014 May;271(2):602-12. doi: 10.1148/radiol.14131969. Epub 2014 Feb 12.

PMID:
24533871
[PubMed - indexed for MEDLINE]
10.

Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.

Eaton BR, Kim HS, Schreibmann E, Schuster DM, Galt JR, Barron B, Kim S, Liu Y, Landry J, Fox T.

J Vasc Interv Radiol. 2014 Feb;25(2):288-95. doi: 10.1016/j.jvir.2013.08.021. Epub 2013 Oct 23.

PMID:
24269792
[PubMed - in process]
11.

Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.

Ulrich G, Dudeck O, Furth C, Ruf J, Grosser OS, Adolf D, Stiebler M, Ricke J, Amthauer H.

J Nucl Med. 2013 Apr;54(4):516-22. doi: 10.2967/jnumed.112.112508. Epub 2013 Feb 27.

PMID:
23447653
[PubMed - indexed for MEDLINE]
Free Article
12.

Imaging discordance between hepatic angiography versus Tc-99m-MAA SPECT/CT: a case series, technical discussion and clinical implications.

Kao YH, Tan EH, Teo TK, Ng CE, Goh SW.

Ann Nucl Med. 2011 Nov;25(9):669-76. doi: 10.1007/s12149-011-0516-9. Epub 2011 Jul 16.

PMID:
21766243
[PubMed - indexed for MEDLINE]
13.

(99m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with (166)Ho-microspheres.

Elschot M, Nijsen JF, Lam MG, Smits ML, Prince JF, Viergever MA, van den Bosch MA, Zonnenberg BA, de Jong HW.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13.

PMID:
24819055
[PubMed - in process]
14.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators.

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.

PMID:
23707371
[PubMed - indexed for MEDLINE]
15.

Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.

Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, Tay KH, Tan BS, Hoe Chow PK, Eng Ng DC, Whatt Goh AS.

J Nucl Med. 2012 Apr;53(4):559-66. doi: 10.2967/jnumed.111.097469. Epub 2012 Feb 17.

PMID:
22343503
[PubMed - indexed for MEDLINE]
Free Article
16.

Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc'h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1057-68. doi: 10.1007/s00259-013-2395-x. Epub 2013 Apr 24.

PMID:
23613103
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Lung dose calculation with SPECT/CT for ⁹⁰Yittrium radioembolization of liver cancer.

Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, Spain J, Xia P, Wilkinson A.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):834-9. doi: 10.1016/j.ijrobp.2012.06.051. Epub 2012 Aug 4.

PMID:
22871239
[PubMed - indexed for MEDLINE]
18.

Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe.

Burgmans MC, Kao YH, Irani FG, Dames EL, Teo TK, Goh AS, Chow PK, Tay KH, Lo RH.

J Vasc Interv Radiol. 2012 Oct;23(10):1294-301. doi: 10.1016/j.jvir.2012.07.009. Epub 2012 Aug 24.

PMID:
22922039
[PubMed - indexed for MEDLINE]
19.

Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A.

J Vasc Interv Radiol. 2004 Apr;15(4):335-45.

PMID:
15064336
[PubMed - indexed for MEDLINE]
20.

Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer.

Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S.

Technol Cancer Res Treat. 2010 Jun;9(3):253-62.

PMID:
20441235
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk